Neuphoria Therapeutics Inc. (NASDAQ:NEUP) stock soared over 20% following the announcement that the company will receive a ...

The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...

GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...

Molnupiravir is under clinical development by Merck and currently in Phase I for Liver Failure (Hepatic Insufficiency). According to GlobalData, Phase I drugs for Liver Failure (Hepatic Insufficiency) ...

Robert F. Kennedy Jr., President Trump’s nominee to be health secretary, would have oversight power over the vaccine’s maker, Merck, if confirmed. By Christina Jewett and Sheryl Gay Stolberg ...

Moderna's recent stumbles make the company an acquisition target. Merck desperately needs Moderna's mRNA-based Personal Cancer Vaccines ("PCVs") to extend KEYTRUDA's patent protection beyond 2028.

Exclusive-Kennedy Played Key Role in Vaccine Case Against Merck By Dan Levine and Mike Spector (Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against ...

The US government has placed an order with Merck & Co to buy 1.7 million courses of its antiviral therapy molnupiravir for COVID-19, assuming it gets approved for use by the FDA. The $1.2 billion ...